Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.8K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.8K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.4K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.4K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

466
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
466
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

15.5K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
15.5K
Disorders of Hemostasis01:24

Disorders of Hemostasis

2.8K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.8K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.5K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bleeding Disorders in Women and Girls: State of the Science and CDC Collaborative Programs.

Journal of women's health (2002)·2022
Same author

Occurrence rates of inherited bleeding disorders other than haemophilia and von Willebrand disease among people receiving care in specialized treatment centres in the United States.

Haemophilia : the official journal of the World Federation of Hemophilia·2022
Same author

The Clinical Genetics of Hemophilia B (Factor IX Deficiency).

The application of clinical genetics·2021
Same author

Women and girls with haemophilia receiving care at specialized haemophilia treatment centres in the United States.

Haemophilia : the official journal of the World Federation of Hemophilia·2021
Same author

The chromogenic Bethesda assay and the Nijmegen-Bethesda assay for factor VIII inhibitors in hemophilia A patients: Are they equivalent?

Journal of thrombosis and haemostasis : JTH·2021
Same author

Monitoring of von Willebrand factor inhibitors in patients with type 3 von Willebrand disease using a quantitative assay.

Haemophilia : the official journal of the World Federation of Hemophilia·2021
Same journal

Tagraxofusp, Azacitidine, and Venetoclax in Blastic Plasmacytoid Dendritic Cell Neoplasm.

Blood·2026
Same journal

Concurrent administration of BCMA and GPRC5D chimeric antigen receptor (CAR) T cells in advanced multiple myeloma.

Blood·2026
Same journal

Single Cell Analysis of the Tumor Microenvironment Landscape Across the Disease Spectrum of Multiple Myeloma.

Blood·2026
Same journal

Decentralized Clinical Trials in Hematology: the Promise and the Peril.

Blood·2026
Same journal

How I Treat Chemotherapy-Induced Thrombocytopenia with Thrombopoietin Receptor Agonists.

Blood·2026
Same journal

The Chaos of Choice in Large B-cell Lymphoma: A Call to Harmonize First-line Trial Design.

Blood·2026
See all related articles

Related Experiment Video

Updated: Apr 5, 2026

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes
12:24

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

Published on: June 3, 2014

12.8K

Game, set, match for factor VIII mismatch?

Connie H Miller1

  • 1CENTERS FOR DISEASE CONTROL AND PREVENTION.

Blood
|August 15, 2015
PubMed
Summary
This summary is machine-generated.

The high rate of factor VIII inhibitors in black hemophilia A patients is not caused by a structural mismatch between treatments and common FVIII genotypes in this population. This finding impacts future hemophilia A treatment strategies.

More Related Videos

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.5K
Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.9K

Related Experiment Videos

Last Updated: Apr 5, 2026

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes
12:24

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

Published on: June 3, 2014

12.8K
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.5K
Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.9K

Area of Science:

  • Hematology
  • Immunology
  • Genetics

Background:

  • Hemophilia A (HA) is a genetic bleeding disorder characterized by deficiency in factor VIII (FVIII).
  • Development of neutralizing antibodies (inhibitors) against FVIII is a major complication in HA treatment, particularly in certain populations.
  • Black patients with hemophilia A exhibit a higher incidence of FVIII inhibitors compared to other ethnic groups.

Purpose of the Study:

  • To investigate the underlying cause of the elevated FVIII inhibitor rates in black patients with hemophilia A.
  • To determine if a genetic mismatch between FVIII treatment products and prevalent FVIII genotypes in black individuals contributes to inhibitor formation.

Main Methods:

  • Analysis of FVIII genotypes in a cohort of black hemophilia A patients.
  • Comparison of these genotypes with the structural characteristics of commonly used FVIII replacement therapies.
  • Assessment of inhibitor development in relation to genotype-treatment compatibility.

Main Results:

  • The study found no significant evidence of a structural mismatch between FVIII treatment products and the FVIII genotypes common among black hemophilia A patients.
  • The observed high rate of inhibitors in this population is unlikely to be solely explained by discrepancies in FVIII protein structure and patient genotype.

Conclusions:

  • The higher prevalence of factor VIII inhibitors in black hemophilia A patients is not attributable to a mismatch between therapeutic FVIII products and their genetic profiles.
  • Further research is needed to elucidate the specific factors contributing to the increased immunogenicity of FVIII in this demographic.